GGHC
RYTM icon

Gilder Gagnon Howe & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,496,424
Closed -$19.5M – 422
2021
Q3 		$19.5M Buy
1,496,424
+7,301
+0.5% +$111K 0.1% 159
2021
Q2 		$29.2M Sell
1,489,123
-34,111
-2% -$708K 0.14% 140
2021
Q1 		$32.4M Buy
1,523,234
+1,137,702
+295% +$33M 0.17% 125
2020
Q4 		$11.5M Buy
+385,532
New +$9.8M 0.06% 179

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's RYTM Position: Q4 2021 in Review

Gilder Gagnon Howe & Co sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2021, closing a stake of 1,496,424 shares — an estimated $19.5M sold.

Gilder Gagnon Howe & Co first reported a position in RYTM in Q4 2020 and held it in 4 quarters. The position peaked at $32.4M in Q1 2021. 98 funds tracked by Wall St. Rank hold RYTM as of Q4 2021.

  • Gilder Gagnon Howe & Co reported no remaining Rhythm Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 1,496,424 Rhythm Pharmaceuticals shares in Q4 2021, an estimated $19.5M.
  • Gilder Gagnon Howe & Co first reported a position in Rhythm Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Rhythm Pharmaceuticals position peaked at $32.4M in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2021, filed 14 Feb 2022.